JP2002506008A5 - - Google Patents

Download PDF

Info

Publication number: JP2002506008A5
Authority: JP; Japan
Prior art keywords: mammal; described method; epc; csf; vascular
Prior art date: 1999-03-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2000535201A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002506008A (ja

Filing date

1999-03-09

Publication date

2006-01-05

1999-03-09 Application filed filed Critical

1999-03-09 Priority claimed from PCT/US1999/005130 external-priority patent/WO1999045775A1/en

2002-02-26 Publication of JP2002506008A publication Critical patent/JP2002506008A/ja

2006-01-05 Publication of JP2002506008A5 publication Critical patent/JP2002506008A5/ja

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 description 60
241000124008 Mammalia Species 0.000 description 33
102000004169 proteins and genes Human genes 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
210000001519 tissue Anatomy 0.000 description 12
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 11
210000004204 blood vessel Anatomy 0.000 description 9
230000002792 vascular Effects 0.000 description 9
230000033115 angiogenesis Effects 0.000 description 8
230000000302 ischemic effect Effects 0.000 description 8
230000003511 endothelial effect Effects 0.000 description 6
239000012634 fragment Substances 0.000 description 6
210000000130 stem cell Anatomy 0.000 description 6
102100034594 Angiopoietin-1 Human genes 0.000 description 5
102100021866 Hepatocyte growth factor Human genes 0.000 description 5
208000024248 Vascular System injury Diseases 0.000 description 5
208000012339 Vascular injury Diseases 0.000 description 5
238000003556 assay Methods 0.000 description 5
208000028867 ischemia Diseases 0.000 description 5
102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
102000014429 Insulin-like growth factor Human genes 0.000 description 4
102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000003226 mitogen Substances 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
108010048154 Angiopoietin-1 Proteins 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
108010041308 Endothelial Growth Factors Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
102100031372 Thymidine phosphorylase Human genes 0.000 description 2
108700023160 Thymidine phosphorylases Proteins 0.000 description 2
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
101800004564 Transforming growth factor alpha Proteins 0.000 description 2
108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 2
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 2
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
102100038217 Vascular endothelial growth factor B Human genes 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
201000002818 limb ischemia Diseases 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
230000003966 vascular damage Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
102000009075 Angiopoietin-2 Human genes 0.000 description 1
108010048036 Angiopoietin-2 Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
210000001956 EPC Anatomy 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
101710177504 Kit ligand Proteins 0.000 description 1
101100481410 Mus musculus Tek gene Proteins 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
239000000587 angiogenesis modulating agent Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1

JP2000535201A 1998-03-09 1999-03-09 血管新生を調整するための組成物及び方法 Withdrawn JP2002506008A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7726298P	1998-03-09	1998-03-09
US60/077,262		1998-03-09
PCT/US1999/005130 WO1999045775A1 (en)	1998-03-09	1999-03-09	Compositions and methods for modulating vascularization

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010157554A Division JP2010265301A (ja)	1998-03-09	2010-07-12	血管新生を調整するための組成物及び方法

Publications (2)

Publication Number	Publication Date
JP2002506008A JP2002506008A (ja)	2002-02-26
JP2002506008A5 true JP2002506008A5 (de)	2006-01-05

Family

ID=22137044

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2000535201A Withdrawn JP2002506008A (ja)	1998-03-09	1999-03-09	血管新生を調整するための組成物及び方法
JP2010157554A Pending JP2010265301A (ja)	1998-03-09	2010-07-12	血管新生を調整するための組成物及び方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2010157554A Pending JP2010265301A (ja)	1998-03-09	2010-07-12	血管新生を調整するための組成物及び方法

Country Status (5)

Country	Link
EP (1)	EP1061800A4 (de)
JP (2)	JP2002506008A (de)
AU (1)	AU766238B2 (de)
CA (1)	CA2322559C (de)
WO (1)	WO1999045775A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2412436C (en) *	2000-06-05	2013-05-21	The Trustees Of Columbia University In The City Of New York	Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
EP1294752A2 (de) *	2000-06-16	2003-03-26	Curis, Inc.	Zusammensetzungen zur modulierung der angiogenese und verwendung
US7547674B2 (en)	2001-06-06	2009-06-16	New York Medical College	Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020061587A1 (en)	2000-07-31	2002-05-23	Piero Anversa	Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en)	2000-07-31	2011-01-04	New York Medical College	Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2421966A1 (en)	2000-09-13	2003-03-11	Chugai Seiyaku Kabushiki Kaisha	Remedies for ischemic diseases
WO2002035992A2 (en) *	2000-10-30	2002-05-10	Children's Medical Center Corporation	Tissue-engineered vascular structures
WO2003043651A1 (en) *	2001-11-19	2003-05-30	Kyowa Hakko Kogyo Co., Ltd.	Drug mobilizing pluripotent stem cells from tissue into peripheral blood
JPWO2003059375A1 (ja) *	2002-01-17	2005-05-19	株式会社カルディオ	組織再生複合療法
KR100562824B1 (ko)	2002-03-20	2006-03-23	주식회사 바이로메드	유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20030199464A1 (en)	2002-04-23	2003-10-23	Silviu Itescu	Regeneration of endogenous myocardial tissue by induction of neovascularization
CN101391105A (zh) *	2002-08-16	2009-03-25	舍林股份公司	以野生型或突变型eNOS对重症肢体缺血的基因治疗
US20040037811A1 (en) *	2002-08-22	2004-02-26	The Cleveland Clinic Foundation	Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
AU2008200822A1 (en) *	2002-08-22	2008-03-13	The Cleveland Clinic Foundation	Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN100366257C (zh) *	2002-08-22	2008-02-06	克里夫兰诊所基金会	基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生
CA2509618A1 (en) *	2002-12-13	2004-07-01	Hisayoshi Fujiwara	Pharmaceutical compositions for treating non-ischemic heart failure
US7695723B2 (en) *	2002-12-31	2010-04-13	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
KR20070008714A (ko) *	2004-04-30	2007-01-17	오르버스네이치 메디칼 인코포레이티드	유전적으로-변형된 세포 포획용 코팅을 갖는 의료 장치 및이의 사용 방법
US20090285785A1 (en) *	2004-09-17	2009-11-19	Cellgentech, Inc.	External Agent for Treatment of Skin Ulcer
TW200637571A (en) *	2005-01-11	2006-11-01	Univ Nagoya Nat Univ Corp	CSF-containing remedy to be administered in low dose
JPWO2006093172A1 (ja) *	2005-02-28	2008-08-07	財団法人先端医療振興財団	成体幹細胞の体外増幅方法
ES2520044T3 (es)	2007-03-30	2014-11-11	The Cleveland Clinic Foundation	SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
CA2743184A1 (en)	2007-11-09	2009-05-14	New York Medical College	Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
EP2227238A2 (de)	2007-11-30	2010-09-15	New York Medical College	Zusammensetzungen mit vaskulären und myozyten-vorläuferzellen und anwendungsverfahren davon
US8124071B2 (en)	2007-11-30	2012-02-28	New York Medical College	Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en)	2007-11-30	2013-08-20	Autologous, Llc	Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009079451A2 (en)	2007-12-14	2009-06-25	The Cleveland Clinic Foundation	Compositions and methods of promoting wound healing
RU2470995C2 (ru)	2008-04-09	2012-12-27	Вайромед Ко., Лтд.	Лиофилизированные днк-составы для увеличенной экспрессии плазмидной днк
CA2772610C (en)	2009-08-28	2018-01-23	The Cleveland Clinic Foundation	Sdf-1 delivery for treating ischemic tissue
US9956265B2 (en)	2011-04-26	2018-05-01	Ajou University Industry-Academic Cooperation Foundation	Composition for aiding surgical procedures for treating ischemic vascular diseases
KR101609690B1 (ko) *	2011-04-26	2016-04-06	아주대학교산학협력단	허혈성 혈관 질환 치료시술 보조용 조성물
KR101336386B1 (ko) *	2011-06-17	2013-12-04	전북대학교병원	림프관 생성 유도제
RU2639582C2 (ru)	2013-10-22	2017-12-21	Виромед Ко., Лтд.	Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов
JP6860474B2 (ja) *	2015-03-18	2021-04-14	公益財団法人神戸医療産業都市推進機構	虚血性疾患の治療及び／又は予防の為の医薬、細胞の血管新生促進活性向上方法、又は、医薬の製造方法
KR20210027493A (ko)	2018-07-19	2021-03-10	주식회사 헬릭스미스	네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4808042A (en) *	1982-06-11	1989-02-28	Electro-Plasma, Inc.	Powder feeder
US4879282A (en) *	1987-03-17	1989-11-07	Saliba Jr Michael J	Medical application for heparin and related molecules
US4808402A (en) *	1987-05-29	1989-02-28	Northwestern University	Method and compositions for modulating neovascularization
US5980887A (en) *	1996-11-08	1999-11-09	St. Elizabeth's Medical Center Of Boston	Methods for enhancing angiogenesis with endothelial progenitor cells
US5880090A (en) *	1997-09-19	1999-03-09	The Hope Heart Institute	Treatment of vascular graft implants with G-CSF

1999
- 1999-03-09 JP JP2000535201A patent/JP2002506008A/ja not_active Withdrawn
- 1999-03-09 CA CA2322559A patent/CA2322559C/en not_active Expired - Fee Related
- 1999-03-09 EP EP99912344A patent/EP1061800A4/de not_active Withdrawn
- 1999-03-09 WO PCT/US1999/005130 patent/WO1999045775A1/en active IP Right Grant
- 1999-03-09 AU AU30737/99A patent/AU766238B2/en not_active Ceased
2010
- 2010-07-12 JP JP2010157554A patent/JP2010265301A/ja active Pending

Publication	Publication Date	Title
JP2002506008A5 (de)	2006-01-05
CA2322559A1 (en)	1999-09-16	Compositions and methods for modulating vascularization
Liu et al.	2013	Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors
JP3866197B2 (ja)	2007-01-10	虚血性疾患治療剤
US20040161421A1 (en)	2004-08-19	Intramyocardial injection of autologous bone marrow
DE60035035T2 (de)	2008-01-31	Injektion von autologem knochenmark in den herzmuskel
Hayon et al.	2012	The role of platelets and their microparticles in rehabilitation of ischemic brain tissue
Weaver et al.	2010	The effects of axial displacement on fracture callus morphology and MSC homing depend on the timing of application
AU772857B2 (en)	2004-05-06	Method of inducing angiogenesis
JP2007501282A (ja)	2007-01-25	哺乳類の四肢の細胞へのポリヌクレオチドの静脈内送達
US20100034794A1 (en)	2010-02-11	Endothelial progenitor cell compositions and neovascularization
JP2023105066A (ja)	2023-07-28	組織治癒剤
KR20060052692A (ko)	2006-05-19	고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드
US20060057722A1 (en)	2006-03-16	Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
EP2431046B1 (de)	2015-02-18	Verwendung von olivenblattextrakten in einer pharmazeutischen zusammensetzung zur induktion von angiogenese und vaskulogenese
AU2005282384B2 (en)	2011-09-01	Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
JP4111950B2 (ja)	2008-07-02	自家骨髄の心筋内注射
JP6923137B2 (ja)	2021-08-18	組織治癒剤
CN113412118A (zh)	2021-09-17	用于预防支架内再狭窄的药物组合物
CN101229366B (zh)	2012-01-11	成纤维细胞生长因子在制备促进血管生成药物中的应用
CN100441226C (zh)	2008-12-10	用于加速创伤修复及防治并发症的方法
Sprengers et al.	2016	Growth factor and cell therapy in patients with critical limb ischemia
JP2003509463A (ja)	2003-03-11	肺系のための細胞ベースの遺伝子治療